Tag Archives: National Cancer Institute

Vision-sparing targeted phototherapy for uveal melanoma

July 30, 2021 by Modulight Content
No comments
Preliminary investigation of AU-011     Related Modulight products and Services   Related Publications Virus-Like Particle-Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens Rhonda C. Kines, Cynthia D. Thompson, Sean Spring, Zhenyu Li, Elisabet de los Pinos, Stephen Monks and John T. Schiller Cancer Immunology Research, 2021, 9 (6)   A Phase 1b/2 Open-label Clinical Trial to Evaluate the Safety and Efficacy of AU-011 for the Treatment of Choroidal Melanoma Prithvi Mruthyunjaya, Amy C. Schefler, Ivana K. Continue reading →Customer case Aura Biosciences, headquartered in Cambridge, MA, is developing a new class of photoactivated therapy for cancer patients together with National Cancer Institute, Emory Eye Center and Wills Eye Hospital. The therapy is based on virus-like conjugates and its primary indication is uveal melanoma. The goal is to eventually develop this technology for multiple cancer indications, such as non-muscle invasive bladder cancer (NMIBC), for which plans are underway to conduct a clinical trial. Dr. Carol Shields, MD – Aura Biosciences Dr. Rhonda Kines, PhD – Continue reading →

Combining photoimmunotherapy with immune checkpoint inhibition

July 14, 2021 by Modulight Content
No comments
Motivation for the study The motivation was to study if photoimmunotherapy could enhance anti-tumor immunity when combined with immune checkpoint inhibition. CD44-targeted photoimmunotherapy was applied against poorly immunogenic, “cold” tumor and antitumor effect was studied alone and in combination with anti-PD-1 immune checkpoint inhibition. Sensitization of this “cold” tumor to immune checkpoint inhibition after photoimmunotherapy would mean that the tumor has been converted into highly immunogenic, “hot” tumor infiltrated with killer T cells mainly responsible for eradicating the tumor. The formation of immunological antitumor memory Continue reading →Customer case The Laboratory of Molecular Theranostics at National Cancer Institute (NCI) is a major research section of the Molecular Imaging Program at National Cancer Institute (NCI) and is led by Dr. Hisataka Kobayashi who is the father of photoimmunotherapy. The ground-breaking research includes the development of imaging and theranostic probes with a particular emphasis on optical probes, which can aid in cancer detection during cancer resection or endoscopy. Dr. Hisataka Kobayashi M.D., PhD Dr. Peter L. Choyke M.D., PhD   Modulight products: ML7710 (multiple channels Continue reading →

ML7710 for photoimmunotherapy against regulatory T cells in tumors

June 14, 2021 by Modulight Content
No comments
    Results Tumor growth was significantly suppressed by photoimmunotherapy, compared to control or IgG without light activation. Tumor growth suppression, as well as overall survival after photoimmunotherapy, were significantly better with F(ab´)2 fragments than with full IgG. This efficacy improvement might be related to killer T cells, which were detected in much higher numbers after photoimmunotherapy with F(ab´)2 fragments and are key cells for the generation of efficient systemic antitumor immunity.       Related Modulight products and Services   Related Publications The Effect Continue reading →Customer case The Laboratory of Molecular Theranostics is a major research section of the Molecular Imaging Program at National Cancer Institute (NCI) and is led by Dr. Hisataka Kobayashi. The groundbreaking research includes the development of imaging and theranostic probes, which can aid in cancer detection and treatment. Dr. Kobayashi has invented near-infrared photoimmunotherapy (NIR-PIT) with IRDye700DX, which is currently in FDA-designated fast-track Phase 3 trials for inoperable Head & Neck cancer. Dr. Hisataka Kobayashi M.D., PhD   Dr. Peter L. Choyke M.D., PhD   Continue reading →

Novel antimicrobial phototherapy against emerging infectious diseases

June 12, 2021 by Modulight Content
No comments
      Results PIAS-treated pathogens were effectively eradicated upon NIR illumination. The efficacy of PIAS was dependent on the NIR light dose, 50 J/cm2 eradicating all MRSA from the rat nasal tract (Figure 1). PIAS also saved all mice from fatal MRSA infections, similar to VCM+RFP antibiotics and even more effectively than VCM antibiotics alone (Figure 2). Unlike the antibiotics, PIAS acted selectively on the target pathogen and did not affect host’s normal intestinal microflora (Figure 3). Also generation of microbial resistance, common problem Continue reading →Customer case Research by: The Jikei University School of Medicine located in Tokyo, Japan and founded in 1881 is today one of the three major private medical schools in Japan. This cutting-edge study was done in close collaboration with Professor Hisataka Kobayashi’s Laboratory of Molecular Theranostics at National Cancer Institute. Modulight products: ML6500 (689 nm, 3 W)   Dr. Makoto Mitsunaga, M.D., PhD   Dr. Tadayuki Iwase, PhD   Dr. Hisataka Kobayashi, M.D., PhD Laser use: Photoimmunotherapy and photochemotherapy of cancer (pancreatic, breast, gastric) and infectious Continue reading →